Navigation Links
Instanyl(R) (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer Pain
Date:9/11/2009

OTFC patients.[2] Instanyl is the First intranasal treatment for breakthrough cancer pain to be licensed and The study showed that 77% of patients preferred Instanyl to OTFC.[2]

"With a preference for Instanyl more than three-fold higher compared to OTFC, the study confirms that with Instanyl patients now have a treatment that they feel better matches their need," said Professor Mercadante and concluded: "Instanyl represents a major step forward in the management of breakthrough cancer pain."

Up to 95% of patients with cancer pain experience breakthrough pain,[3] Of which two-thirds experience inadequate pain control.[4] Interim results From the first European survey of breakthrough cancer pain[5] also presented for the first time in Lisbon show that on average a patient will have 3 episodes of BTCP per day, each one lasting on average 60 minutes and 96% of episodes being rated as moderate or severe. 87% of patients reported that their BTCP interfered with their daily living including their ability to sleep, walk and get on with other people.

"Breakthrough cancer pain afflicts a large proportion of cancer patients, yet there is a significant under-treatment and sub-optimal treatment of these patients. Time has come for a change in management of breakthrough cancer pain and with Instanyl now approved we have an intranasal product with fast onset of pain relief, short duration which is easy to use. This will enable us to improve the care of cancer patients," commented President of EFIC, Professor Giustino Varrassi, Dept. of Anesthesiology and Pain Medicine L'Aquila University, Italy.

Instanyl is approved for the management of breakthrough cancer pain in adults already receiving maintenance opioid therapy for chronic cancer pain. This first-in class drug was granted marketing authorisation on the 20th July 2009, and will be launched across Europe from September 2009.

About Nyco
'/>"/>

SOURCE Nycomed
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window
2. University of Michigan Study Shows SEQUENOMs MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
3. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
4. Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors
5. Angiomax Will Retain Decision Resources Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI
6. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
7. Study Shows No Standardized Approach to Epidural Steroid Injections for Back Pain
8. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
9. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
10. Siemens Introduces New Standard of Care for Breast Ultrasound
11. Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... FRAMINGHAM, Mass. , Jan. 14, 2014 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that it expects revenues for the ... bringing expected full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... N.J. , Aug. 2 Octapharma ... from the U.S. Food and Drug Administration (FDA) ... the replacement therapy developed specifically for von Willebrand Disease (VWD). ... Products Development , which helps to advance the development of ...
... EMERYVILLE, Calif. , Aug. 2 Bionovo, ... results from studies in neurons of its drug candidate Menerba ... in the Public Library of Science (PLoS) One, describes a ... from stem cells, and express native estrogen receptors. Menerba, an ...
Cached Medicine Technology:FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USA's New Therapy for Common Inherited Bleeding Disorder 2FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USA's New Therapy for Common Inherited Bleeding Disorder 3FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USA's New Therapy for Common Inherited Bleeding Disorder 4FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USA's New Therapy for Common Inherited Bleeding Disorder 5Bionovo Announces Publication Describing Menerba's Effect on Neural Pathways Related to Temperature Regulation 2Bionovo Announces Publication Describing Menerba's Effect on Neural Pathways Related to Temperature Regulation 3Bionovo Announces Publication Describing Menerba's Effect on Neural Pathways Related to Temperature Regulation 4
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... Programming Announced in Lead Up to World AIDS Day (Dec. ... PARK, Calif., Nov. 26 For more than ten years, ... the U.S. and abroad to reach the public with information ... surrounding the disease. The Foundation,s media partnerships leverage significant ...
... 26, 2008 The American Society for Gastrointestinal ... in U.S. cancer deaths and incidence rates, with colorectal ... ASGE, representing the specialists in colorectal cancer screening, is ... among men and women dropped 4.3 percent per year ...
... of Matthew L. Myers President, Campaign for Tobacco-Free Kids ... 26 Guatemala,s Congress on November 24, 2008, approved ... places, including restaurants and bars, be 100 percent smoke-free. ... protecting the health of Guatemala,s 13 million residents and ...
... it,s cheaper and less time-consuming than in-person visits, study ... counseling may be as effective as face-to-face counseling in ... University of Florida study included 234 obese women, ages ... Florida. , All the women completed a six-month weight-loss ...
... of our genetic material--about 2%-- performs the crucial task scientists ... serve as a blueprint for the production of proteins, the ... of human DNA is converted into intermediary molecules called RNAs, ... , And what of the other 98% of the ...
... taste sensation of rats to sweet foods and drives ... neuroscientists. Findings from the Penn State study could uncover ... reveal how flab hooks the brain on sugary food., ... you tend to consume it in higher amounts," said ...
Cached Medicine News:Health News:Kaiser Family Foundation Partners With Media Around The Globe to Address HIV/AIDS 2Health News:Kaiser Family Foundation Partners With Media Around The Globe to Address HIV/AIDS 3Health News:Kaiser Family Foundation Partners With Media Around The Globe to Address HIV/AIDS 4Health News:Kaiser Family Foundation Partners With Media Around The Globe to Address HIV/AIDS 5Health News:ASGE encouraged by drop in colorectal cancer deaths 2Health News:Guatemala's Congress Takes Action to Save Lives By Approving Strong Smoke-free Legislation 2Health News:Guatemala's Congress Takes Action to Save Lives By Approving Strong Smoke-free Legislation 3Health News:Over-the-Phone Weight Loss Counseling Works 2Health News:Scientists at CSHL uncover new RNA processing mechanism and a new class of small RNAs 2Health News:Scientists at CSHL uncover new RNA processing mechanism and a new class of small RNAs 3Health News:Route to obesity passes through tongue 2Health News:Route to obesity passes through tongue 3
ReNu 1 Step Enzymatic Cleaner with ReNu Multi-Purpose Solution removes protein deposits while lenses are being disinfected. Its a one-step process that saves time. Removes stubborn deposits from dai...
...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
... intraocular lenses. The instrument consists of a ... implant and divides the implant into two ... halves of the lens so that unwanted ... chamber is avoided. The instrument is passed ...
Medicine Products: